Multiple Sclerosis Lecture Series: Current Concepts

Wednesday, June 15, 2022, 12:00 AM - Saturday, June 14, 2025, 11:59 PM, On Demand

Internet Enduring Material sponsored by Stanford University School of Medicine. Presented by the Stanford University School of Medicine Department of Neurology and Center for Continuing Medical Education.

What are the early treatment possibilities for Multiple Sclerosis? In the third lecture of the MS Lecture Series, learn about MS phenotypes, the importance of early intervention, and maximizing neurological reserve in patients. Treatments for Multiple Sclerosis continue to evolve, so watch this video to learn the latest concepts and best practices for treating MS patients quickly after diagnosis.

     Release Date: June 15, 2022
     Expiration Date: June 14, 2025
     Estimated Time to Complete: 34 minutes 
     Registration Fee: FREE 

AMA PRA Category 1 Credits™ (0.50 hours), Non-Physician Participation Credit (0.50 hours)

1. Summarize the positive impact of early treatment in Multiple Sclerosis.
2. Utilize pharmacologic and non-pharmacologic therapies to maximize neurological reserve.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, please contact the CME office.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References/Bibliography

Bermel, Robert A., and Rohit Bakshi. “The Measurement and Clinical Relevance of Brain Atrophy in Multiple Sclerosis.” The Lancet Neurology 5, no. 2 (February 1, 2006): 158–70. https://doi.org/10.1016/S1474-4422(06)70349-0.

Cohen, Jeffrey A., Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Bhupendra O. Khatri, Xavier Montalban, Jean Pelletier, et al. “Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis.” New England Journal of Medicine 362, no. 5 (February 4, 2010): 402–15. https://doi.org/10.1056/NEJMoa0907839.

Comi, Giancarlo, Marta Radaelli, and Per Soelberg Sørensen. “Evolving Concepts in the Treatment of Relapsing Multiple Sclerosis.” The Lancet 389, no. 10076 (April 1, 2017): 1347–56. https://doi.org/10.1016/S0140-6736(16)32388-1.

Criste, Gerson, Bruce Trapp, and Ranjan Dutta. “Chapter 5 - Axonal Loss in Multiple Sclerosis: Causes and Mechanisms.” In Handbook of Clinical Neurology, edited by Douglas S. Goodin, 122:101–13. Multiple Sclerosis and Related Disorders. Elsevier, 2014. https://doi.org/10.1016/B978-0-444-52001-2.00005-4.

De Stefano, Nicola, Maria Laura Stromillo, Antonio Giorgio, Maria Letizia Bartolozzi, Marco Battaglini, Mariella Baldini, Emilio Portaccio, Maria Pia Amato, and Maria Pia Sormani. “Establishing Pathological Cut-Offs of Brain Atrophy Rates in Multiple Sclerosis.” Journal of Neurology, Neurosurgery & Psychiatry 87, no. 1 (January 1, 2016): 93. https://doi.org/10.1136/jnnp-2014-309903.

D’hooghe, MB, G. Nagels, V. Bissay, and J. De Keyser. “Modifiable Factors Influencing Relapses and Disability in Multiple Sclerosis.” Multiple Sclerosis Journal 16, no. 7 (July 1, 2010): 773–85. https://doi.org/10.1177/1352458510367721.

Fisniku, L. K., P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton, R. Lanyon, A. J. Thompson, and D. H. Miller. “Disability and T2 MRI Lesions: A 20-Year Follow-up of Patients with Relapse Onset of Multiple Sclerosis.” Brain 131, no. 3 (March 1, 2008): 808–17. https://doi.org/10.1093/brain/awm329.

Freedman, Mark S., Giancarlo Comi, Nicola De Stefano, Frederik Barkhof, Chris H. Polman, Bernard M.J. Uitdehaag, Lorenz Lehr, Bettina Stubinski, and Ludwig Kappos. “Moving toward Earlier Treatment of Multiple Sclerosis: Findings from a Decade of Clinical Trials and Implications for Clinical Practice.” Multiple Sclerosis and Related Disorders 3, no. 2 (March 1, 2014): 147–55. https://doi.org/10.1016/j.msard.2013.07.001.

Giovannoni, Gavin, Helmut Butzkueven, Suhayl Dhib-Jalbut, Jeremy Hobart, Gisela Kobelt, George Pepper, Maria Pia Sormani, Christoph Thalheim, Anthony Traboulsee, and Timothy Vollmer. “Brain Health: Time Matters in Multiple Sclerosis.” Multiple Sclerosis and Related Disorders 9 (September 1, 2016): S5–48. https://doi.org/10.1016/j.msard.2016.07.003.

He, Anna, Bernd Merkel, James William L Brown, Lana Zhovits Ryerson, Ilya Kister, Charles B Malpas, Sifat Sharmin, et al. “Timing of High-Efficacy Therapy for Multiple Sclerosis: A Retrospective Observational Cohort Study.” The Lancet Neurology 19, no. 4 (April 1, 2020): 307–16. https://doi.org/10.1016/S1474-4422(20)30067-3.

Heine, Martin, Olaf Verschuren, Erwin LJ Hoogervorst, Erik van Munster, Hub GA Hacking, Anne Visser-Meily, Jos WR Twisk, Heleen Beckerman, Vincent de Groot, and Gert Kwakkel. “Does Aerobic Training Alleviate Fatigue and Improve Societal Participation in Patients with Multiple Sclerosis? A Randomized Controlled Trial.” Multiple Sclerosis Journal 23, no. 11 (October 1, 2017): 1517–26. https://doi.org/10.1177/1352458517696596.

Inc, MULTILEARNING Group. “Effect of Smoking, a NAT1 Genetic Variant and HLA Genes on Disease... by Ms. Eva Rosa Petersen.” Accessed June 3, 2022. https://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/147025/eva.rosa.petersen.effect.of.smoking.a.nat1.genetic.variant.and.hla.genes.on.html?f=m3.

Kappus, Natalie, Bianca Weinstock-Guttman, Jesper Hagemeier, Cheryl Kennedy, Rebecca Melia, Ellen Carl, Deepa P Ramasamy, et al. “Cardiovascular Risk Factors Are Associated with Increased Lesion Burden and Brain Atrophy in Multiple Sclerosis.” Journal of Neurology, Neurosurgery & Psychiatry 87, no. 2 (February 1, 2016): 181. https://doi.org/10.1136/jnnp-2014-310051.

Katz Sand, Ilana, Stephen Krieger, Colleen Farrell, and Aaron E Miller. “Diagnostic Uncertainty during the Transition to Secondary Progressive Multiple Sclerosis.” Multiple Sclerosis Journal 20, no. 12 (October 1, 2014): 1654–57. https://doi.org/10.1177/1352458514521517.

Kavaliunas, Andrius, Ali Manouchehrinia, Leszek Stawiarz, Ryan Ramanujam, Jonas Agholme, Anna Karin Hedström, Omid Beiki, Anna Glaser, and Jan Hillert. “Importance of Early Treatment Initiation in the Clinical Course of Multiple Sclerosis.” Multiple Sclerosis Journal 23, no. 9 (August 1, 2017): 1233–40. https://doi.org/10.1177/1352458516675039.

Krieger, Stephen C., Karin Cook, Scott De Nino, and Madhuri Fletcher. “The Topographical Model of Multiple Sclerosis: A Dynamic Visualization of Disease Course.” Neurology - Neuroimmunology Neuroinflammation 3, no. 5 (October 1, 2016). https://doi.org/10.1212/NXI.0000000000000279.
Lublin, Fred D., Stephen C. Reingold, Jeffrey A. Cohen, Gary R. Cutter, Per Soelberg Sørensen, Alan J. Thompson, Jerry S. Wolinsky, et al. “Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions.” Neurology 83, no. 3 (July 15, 2014): 278–86. https://doi.org/10.1212/WNL.0000000000000560.

Lublin, Fred D., Stephen C. Reingold, and National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis*. “Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey.” Neurology 46, no. 4 (April 1, 1996): 907–11. https://doi.org/10.1212/WNL.46.4.907.

Nishanth, Katukuri, Ezza Tariq, Farirai P. Nzvere, Mohammed Miqdad, and Ivan Cancarevic. “Role of Smoking in the Pathogenesis of Multiple Sclerosis: A Review Article.” Cureus 12, no. 8 (August 5, 2020). https://doi.org/10.7759/cureus.9564.

Özcan, Muhammed Emin, Bahri Ince, Ayhan Bingöl, Simge Ertürk, Meriç Adil Altinöz, Hasan Hüseyin Karadeli, Abdulkadir Koçer, and Talip Asil. “Association between Smoking and Cognitive Impairment in Multiple Sclerosis.” Neuropsychiatric Disease and Treatment 10 (September 10, 2014): 1715–19. https://doi.org/10.2147/NDT.S68389.

Prakash, Ruchika Shaurya, Erin M. Snook, Robert W. Motl, and Arthur F. Kramer. “Aerobic Fitness Is Associated with Gray Matter Volume and White Matter Integrity in Multiple Sclerosis.” Exercise and the Brain 1341 (June 23, 2010): 41–51. https://doi.org/10.1016/j.brainres.2009.06.063.

“Roche | MS Measurements Explained.” Accessed June 3, 2022. https://www.roche.com/stories/measuring-multiple-sclerosis-a-glossary.

Scalfari, Antonio, Anneke Neuhaus, Martin Daumer, Paolo Antonio Muraro, and George Cornell Ebers. “Onset of Secondary Progressive Phase and Long-Term Evolution of Multiple Sclerosis.” Journal of Neurology, Neurosurgery & Psychiatry 85, no. 1 (January 1, 2014): 67–75. https://doi.org/10.1136/jnnp-2012-304333.

Scalfari, Antonio, Anneke Neuhaus, Alexandra Degenhardt, George P. Rice, Paolo A. Muraro, Martin Daumer, and George C. Ebers. “The Natural History of Multiple Sclerosis, a Geographically Based Study 10: Relapses and Long-Term Disability.” Brain 133, no. 7 (July 1, 2010): 1914–29. https://doi.org/10.1093/brain/awq118.

Tettey, Prudence, Steve Simpson Jr., Bruce V. Taylor, and Ingrid A.F. van der Mei. “Vascular Comorbidities in the Onset and Progression of Multiple Sclerosis.” Journal of the Neurological Sciences 347, no. 1 (December 15, 2014): 23–33. https://doi.org/10.1016/j.jns.2014.10.020.

Trapp, Bruce D., Lars Bö, Sverre Mörk, and Ansi Chang. “Pathogenesis of Tissue Injury in MS Lesions.” Journal of Neuroimmunology 98, no. 1 (July 1, 1999): 49–56. https://doi.org/10.1016/S0165-5728(99)00081-8.

Trapp, Bruce D., Richard M. Ransohoff, Elizabeth Fisher, and Richard A. Rudick. “Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability.” The Neuroscientist 5, no. 1 (January 1, 1999): 48–57. https://doi.org/10.1177/107385849900500107.

Trapp, Bruce D., Richard Ransohoff, and Richard Rudick. “Axonal Pathology in Multiple Sclerosis: Relationship to Neurologic Disability.” Current Opinion in Neurology 12, no. 3 (June 1999): 295–302.

Trojano, Maria, Fabio Pellegrini, Aurora Fuiani, Damiano Paolicelli, Valentina Zipoli, Giovanni B. Zimatore, Elisabetta Di Monte, et al. “New Natural History of Interferon-β–Treated Relapsing Multiple Sclerosis.” Annals of Neurology 61, no. 4 (April 1, 2007): 300–306. https://doi.org/10.1002/ana.21102.

National Multiple Sclerosis Society. “Vitamin D.” Accessed June 3, 2022. https://www.nationalmssociety.org/Research/Research-News-Progress/Vitamin-D.

Watkins, Jack L., Premal H. Thaker, Alpa M. Nick, Lois M. Ramondetta, Sanjeev Kumar, Diana L. Urbauer, Koji Matsuo, et al. “Clinical Impact of Selective and Nonselective Beta-Blockers on Survival in Patients with Ovarian Cancer.” Cancer 121, no. 19 (2015): 3444–51. https://doi.org/10.1002/cncr.29392.

Zivadinov, R., B. Weinstock-Guttman, K. Hashmi, N. Abdelrahman, M. Stosic, M. Dwyer, S. Hussein, J. Durfee, and M. Ramanathan. “Smoking Is Associated with Increased Lesion Volumes and Brain Atrophy in Multiple Sclerosis.” Neurology 73, no. 7 (August 18, 2009): 504. https://doi.org/10.1212/WNL.0b013e3181b2a706.

For activity related questions, please contact
     Name: Holly Meyer
     Title: CME Coordinator
     Email: [email protected]

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education. 

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

This educational activity is supported in part by an educational grant from Novartis Pharmaceuticals Corporation.